title: Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
authors.forename: Muhammet Fuat
authors.initials: MF
authors.lastname: Ozcan
authors.forename: Abdullah Erdem
authors.initials: AE
authors.lastname: Canda
authors.forename: Omer
authors.initials: O
authors.lastname: Dizdar
authors.forename: Serkan
authors.initials: S
authors.lastname: Altinova
authors.forename: Ziya
authors.initials: Z
authors.lastname: Akbulut
authors.forename: Mevlana Derya
authors.initials: MD
authors.lastname: Balbay
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000556:secondary; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000401:mortality / Q000473:pathology; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015996:Survival Rate; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases